Georgia Medicare Cervical Cancer Screening 2026 Guide

If you are a woman on Medicare in Georgia, cervical cancer screening is covered at $0, but many beneficiaries face a real decision at age 65: keep screening, or stop. Original Medicare pays the full cost of the screening Pap test, pelvic examination, and human papillomavirus (HPV) co-testing when your provider accepts assignment, with no Part B deductible or coinsurance.1 Timing and eligibility drive the rest: average-risk women are covered every 24 months, high-risk women every 12 months, and HPV co-testing every 5 years for ages 30 to 65. Whether you should keep screening past 65 turns on your prior results, not your age alone.

This guide is written for Georgia's Medicare women and the families helping them, and it covers the age-65 discontinuation rules from the U.S. Preventive Services Task Force (USPSTF). Georgia's cervical cancer mortality falls hardest on African American and Hispanic women, which makes an accurate, individualized screening decision at the Annual Wellness Visit especially important.

How Medicare Came to Cover Cervical Cancer Screening

Section 1861(nn) of the Social Security Act

Section 1861(nn) of the Social Security Act (42 U.S.C. 1395x(nn)) defines "screening pap smear and screening pelvic examination" for Medicare coverage purposes. The statutory definition includes:

• A diagnostic laboratory test consisting of a routine exfoliative cytology test (Pap test) of cervical or vaginal cells.
• A screening pelvic examination including a clinical breast examination as part of the pelvic visit.
• HPV testing when furnished as part of a screening pelvic examination consistent with CMS coverage decisions.

The statute also requires that the screening be performed by a physician or qualified non-physician practitioner.

Section 6113: Where the Pap Test Benefit Began (1989)

The screening Pap test benefit was established by Section 6113 of the Omnibus Budget Reconciliation Act of 1989 (Public Law 101-239), signed December 19, 1989. The Pap test benefit became effective for services furnished on or after July 1, 1990. The original frequency was every 3 years for low-risk women and every 12 months for high-risk women.

BBA 1997 Section 4102: Adding the Pelvic Examination

Section 4102 of the Balanced Budget Act of 1997 (BBA, Public Law 105-33), signed August 5, 1997, added the screening pelvic examination as a covered service. The pelvic examination is performed in conjunction with the Pap test and includes the clinical breast examination.

HPV Co-Testing Coverage Expansion (NCD 210.2, July 9, 2015)

CMS has updated the frequency rules through implementing regulations and National Coverage Determinations. CMS issued National Coverage Determination 210.2 expanding Medicare coverage to include HPV testing in combination with the Pap test (co-testing) for women age 30 to 65 effective July 9, 2015. The coverage applies once every 5 years for asymptomatic average-risk women age 30 to 65 who meet the screening criteria.1

This expansion reflected accumulated evidence that HPV testing improves screening sensitivity, particularly for the detection of adenocarcinoma, which is less well-detected by cytology alone. HPV testing also supports longer screening intervals (5 years for co-testing versus 3 years for cytology alone) because of its higher negative predictive value.

42 CFR 410.56 Implementing Regulations

The implementing regulations for cervical and vaginal cancer screening are codified at 42 CFR 410.56. The regulations specify:

• The covered services: screening Pap test, screening pelvic examination, HPV co-testing.
• The frequency limits by risk category.
• The high-risk category definitions.
• The provider requirements (physician or qualified non-physician practitioner).
• The clinical laboratory requirements for cytopathology and HPV testing.

Related Statutory and Regulatory Authority

Several other Medicare preventive services statutes coordinate with the cervical cancer screening benefit:

• Section 1861(ww) SSA: Initial Preventive Physical Examination (IPPE, Welcome to Medicare visit).
• Section 1861(hhh) SSA: Annual Wellness Visit (AWV).
• Section 1861(ddd) SSA: general preventive services framework.
• ACA Section 4104 (Public Law 111-148): preventive services cost-sharing waiver effective January 1, 2011.

Who Qualifies for Medicare Cervical Cancer Screening in Georgia?

Sex Eligibility

Cervical cancer screening under Section 1861(nn) is specifically defined as a service for women beneficiaries.

Age Eligibility

Medicare covers cervical cancer screening for women beneficiaries without an explicit lower age limit (women under age 35 who enroll in Medicare through disability eligibility may receive screening). There is no upper age limit either.

Risk Stratification

Medicare uses two risk categories for cervical cancer screening:

Average risk applies to women without any qualifying high-risk factor. Average-risk frequency is every 24 months for the screening Pap test and pelvic examination.

High risk applies to women with at least one qualifying high-risk factor. High-risk frequency is every 12 months (annually).1

High-Risk Category Definitions

The implementing regulations and CMS sub-regulatory guidance define the following high-risk categories for cervical cancer screening:

1. Personal history of cervical cancer or vaginal cancer: prior diagnosis requires ongoing surveillance with annual screening.
2. Abnormal cytology within the past 3 years: a prior abnormal Pap test (ASCUS, LSIL, HSIL, AGC, AIS) within the past 3 years triggers high-risk classification.
3. History of cervical intraepithelial neoplasia (CIN) grade 2 or 3: prior CIN 2 or CIN 3 lesions require ongoing surveillance.
4. DES exposure: women exposed in utero to diethylstilbestrol (DES) prior to 1971 face elevated risk of clear cell adenocarcinoma of the cervix and vagina.
5. HIV infection or immunocompromise: HIV-infected women, organ transplant recipients on immunosuppressive therapy, and women receiving immunosuppressive treatment for autoimmune disease face elevated risk.
6. Other documented high-risk factors: including certain occupational exposures, a history of cervical pre-cancer treatment, and other documented risk factors at provider discretion.

USPSTF 2018 Recommendation Framework

The USPSTF 2018 update represents the current recommended framework:

• Women age 21 to 29: Pap test every 3 years (cytology alone). The USPSTF does not recommend HPV testing for women under age 30 due to high HPV prevalence with low cancer progression risk.
• Women age 30 to 65: three options, a Pap test every 3 years (cytology alone), HPV testing every 5 years (primary HPV testing), or Pap and HPV co-testing every 5 years.
• Women older than 65: recommend against screening for women with adequate prior negative screening (three consecutive negative Pap tests or two consecutive negative HPV tests/co-tests within the past 10 years, most recent within the past 5 years).
• Women with prior hysterectomy: recommend against screening for women who have had a hysterectomy with removal of the cervix and who do not have a history of high-grade precancerous lesion or cervical cancer.

The USPSTF Grade A recommendation qualifies cervical cancer screening for the ACA Section 4104 cost-sharing waiver.

The Age-65 Decision: Continue or Discontinue

The age-65 recommendation above matters most to the Medicare population because most beneficiaries enroll at 65, and discontinuation requires that the adequate-prior-screening history be documented. Women with inadequate prior screening, prior abnormal results, or other risk factors should continue screening according to their individual risk profile.

What Cervical Cancer Screening Tests Does Medicare Cover?

Screening Pap Test (Cytology)

The Pap test (papanicolaou smear) collects cells from the cervix using a brush or spatula. The cells are then fixed and stained for cytologic examination under a microscope to identify atypical or malignant cells.

Two technical approaches to Pap testing exist:

• Conventional Pap smear: cells are smeared directly onto a glass slide at the bedside.
• Liquid-based cytology: cells are suspended in a liquid preservative and processed in the laboratory. This is the dominant approach in modern practice.

Screening Pelvic Examination

The pelvic examination is a clinical examination performed by a physician or qualified non-physician practitioner. It typically includes:

• External examination: inspection of the vulva and perineum.
• Speculum examination: inspection of the vagina and cervix.
• Bimanual examination: palpation of the uterus and adnexa.
• Clinical breast examination: palpation of the breasts and axillae.

HPV Co-Testing

Human papillomavirus (HPV) testing identifies the presence of high-risk HPV types (most importantly HPV 16 and HPV 18, the leading high-risk types associated with cervical cancer) through molecular testing of cervical samples. HPV co-testing combines HPV testing with cytology in a single screening encounter.

Medicare covers HPV testing as part of co-testing for women age 30 to 65 every 5 years under HCPCS G0476.

Coverage Code Summary

A typical screening encounter generates several of these codes at once.

What Does Medicare Cervical Cancer Screening Cost in Georgia?

Why Screening Is $0

Section 4104 of the Affordable Care Act (Public Law 111-148) eliminated the Part B deductible and coinsurance for USPSTF Grade A or B preventive services effective January 1, 2011. The USPSTF has graded cervical cancer screening Grade A, qualifying it for the ACA Section 4104 cost-sharing waiver.

Beneficiaries therefore pay $0 for the screening Pap test, pelvic examination, and HPV co-testing when the provider accepts Medicare.1

When Follow-Up Care Costs More

When a screening Pap test or HPV test identifies abnormal findings requiring additional evaluation, the beneficiary enters a diagnostic pathway with different cost-sharing. Typical diagnostic procedures include:

• Colposcopy: direct visual examination of the cervix using a colposcope to identify abnormal areas for biopsy. Subject to standard Part B cost-sharing.
• Cervical biopsy: tissue sampling from suspicious cervical areas during colposcopy. Subject to standard Part B cost-sharing.
• Endocervical curettage: sampling of cells from the endocervical canal. Subject to standard Part B cost-sharing.
• LEEP (Loop Electrosurgical Excision Procedure): therapeutic procedure for high-grade lesions. Subject to standard Part B cost-sharing.
• Cone biopsy: excisional procedure for diagnosis or treatment of high-grade lesions. Subject to standard Part B cost-sharing.

For these diagnostic procedures, the beneficiary pays the annual Part B deductible plus 20% coinsurance of the Medicare-approved amount.2

Cost-Sharing Summary Table

How Screening Fits With Your Annual Wellness Visit and Other Care

Coordination With the Annual Wellness Visit

The Medicare Annual Wellness Visit (AWV), authorized by Section 1861(hhh) of the Social Security Act, includes a personalized prevention plan that documents preventive services status and recommendations. Cervical cancer screening is a routine AWV component for women beneficiaries:

• Documentation of the most recent Pap test, HPV test, or co-test results.
• Documentation of prior abnormal results and surveillance status.
• Risk assessment for high-risk categorization.
• The age-65 continue-or-discontinue discussion described above.
• Coordination with other Medicare preventive services.

Coordination With the Initial Preventive Physical Examination

The Medicare Initial Preventive Physical Examination (IPPE), authorized by Section 1861(ww), is the one-time preventive visit available within the first 12 months of Part B enrollment. The IPPE includes an assessment of preventive services needs and orders for appropriate screening, including cervical cancer screening when indicated.

Coordination With Colposcopy and Diagnostic Workup

Abnormal cervical cancer screening results require timely diagnostic workup. The American Society for Colposcopy and Cervical Pathology (ASCCP) maintains evidence-based management guidelines specifying triage of abnormal Pap and HPV results. Common pathways include:

• ASCUS Pap with positive HPV: colposcopy.
• LSIL Pap: colposcopy.
• HSIL Pap: colposcopy with biopsy.
• AGC Pap: colposcopy with endocervical curettage.
• AIS Pap: colposcopy with endocervical curettage and possible cone biopsy.
• Persistent HPV without cytologic abnormality: repeat testing or colposcopy depending on age and HPV type.

Who Can Perform Your Screening?

Provider Categories

Cervical cancer screening services are performed by:

• Gynecologists: obstetrician-gynecologists with subspecialty training in women's health.
• Family medicine physicians: many provide women's health services, including cervical cancer screening.
• Internal medicine physicians: some internists provide cervical cancer screening, particularly when integrated with primary care.
• Nurse practitioners and physician assistants: within scope of practice and state licensure rules.
• Certified nurse-midwives: within scope of practice.

Clinical Laboratory Requirements

Cytopathology screening and HPV testing are performed in Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories with appropriate accreditation for high-complexity testing. The clinical laboratory provides cytotechnologists who perform initial screening and cytopathologists (pathologists with cytopathology subspecialty) who interpret abnormal findings.

Georgia Provider Licensure

In Georgia, gynecologists, family medicine physicians, and internal medicine physicians are licensed by the Georgia Composite Medical Board. Nurse practitioners, physician assistants, and certified nurse-midwives are licensed by the relevant Georgia licensing boards.

Where to Get Screened in Georgia

Atlanta Metropolitan Area

The Atlanta metropolitan area has extensive gynecology and women's health capacity:

• Emory Gynecology: academic gynecology at Emory University with comprehensive women's health services.
• Wellstar Women's Health: network-wide women's health coverage across the north and west Atlanta metropolitan area.
• Piedmont Women's Health: Piedmont Healthcare women's health services.
• Northside Hospital Women's Services: a particularly strong women's health presence in the north Atlanta area.
• Grady Women's Center: safety-net women's health serving central Atlanta.
• Emory Winship Cancer Institute Gynecologic Oncology: comprehensive gynecologic oncology for cervical cancer treatment.

Augusta and East Georgia

Augusta University Women's Health serves east Georgia with academic gynecology and gynecologic oncology services through the Georgia Cancer Center.

Macon and Central Georgia

Atrium Health Navicent (Macon) and Coliseum Medical Centers provide women's health services for central Georgia.

Savannah and Coastal Georgia

Memorial Health (Savannah) and St. Joseph's/Candler Health System provide women's health services for coastal Georgia.

Albany and Southwest Georgia

Phoebe Putney Memorial Hospital (Albany) is the primary women's health resource for southwest Georgia.

Athens and Northeast Georgia

Piedmont Athens Regional and St. Mary's Health Care System provide women's health services for the Athens area and northeast Georgia.

Federally Qualified Health Centers (FQHCs)

Georgia's Federally Qualified Health Centers (FQHCs) provide women's health and cervical cancer screening services for medically underserved populations. Many FQHCs partner with the Georgia Department of Public Health Breast and Cervical Cancer Program (BCCP) to provide screening services for uninsured women.

Rural Georgia Access

Many rural Georgia counties lack local gynecology providers. Beneficiaries in counties without local gynecology access typically receive cervical cancer screening from family medicine physicians or nurse practitioners. When an abnormal screening requires colposcopy, beneficiaries typically travel to regional medical centers (Albany, Macon, Augusta, Savannah, Athens, Atlanta) for specialty care.

Cervical Cancer in Georgia: Who Is Most at Risk

Incidence and Mortality

Cervical cancer incidence in the United States has declined dramatically since the introduction of Pap test screening, but persistent disparities affect underserved populations. In Georgia, cervical cancer mortality is elevated in African American women compared to non-Hispanic white women, reflecting lower screening uptake, later-stage diagnosis at presentation, treatment access disparities, and persistent socioeconomic health disparities. Hispanic women face elevated incidence rates, particularly among immigrant populations with limited screening access in their countries of origin. Proactive engagement at the Annual Wellness Visit, to settle screening adequacy and the discontinuation question, matters most for these populations.

Georgia's Breast and Cervical Cancer Program

The Georgia Department of Public Health operates the Breast and Cervical Cancer Program (BCCP), which provides cervical cancer screening for uninsured low-income women. Women diagnosed with cervical cancer or pre-cancer through BCCP qualify for Medicaid coverage under the Breast and Cervical Cancer Prevention and Treatment Act of 2000 (42 U.S.C. 1396a(a)(10)(A)(ii)(XVIII)). This pathway primarily serves women under age 65; Medicare women beneficiaries generally receive screening under Medicare rather than BCCP.

HPV Vaccination Impact

The HPV vaccine, recommended for adolescents and young adults, is expected to substantially reduce cervical cancer incidence in future cohorts. The impact on the current Medicare population is limited, however, because most Medicare women aged out of the vaccination age range before the vaccine became available. The vaccine's impact will become more relevant for Medicare cohorts after the early HPV-vaccinated cohorts (born approximately 1990 and later) age into Medicare in the 2050s.

How the Rules Play Out: Example Scenarios

The scenarios below are hypothetical and illustrative. They show how the rules apply; they are not accounts of real patients.

Scenario #1: Atlanta, Age 66, No Adequate Prior Screening

A 66-year-old woman in Fulton County has had no Pap test in the past 10 years and is average risk. At her AWV with her primary care physician at Grady Health System, the physician documents the lack of adequate prior screening, so she requires continued screening.

She is screened at $01 and both results come back negative: Pap negative for intraepithelial lesion or malignancy (NILM), HPV negative for high-risk types. She now has one negative Pap and one negative HPV co-test, and would need additional negative screenings before meeting the adequate-prior-screening criteria for discontinuation. Her next co-testing is 5 years out, at about age 71.

Scenario #2: Rural Southwest Georgia, Abnormal Result

A 67-year-old woman in Worth County has no local gynecologist; her family medicine physician at an FQHC handles women's health. The physician documents the absence of adequate prior screening (no Pap test in over 10 years), performs the examination (G0101), obtains the Pap sample (Q0091), and sends it to a reference laboratory for liquid-based cytology (G0123) and HPV co-testing (G0476).

Results: Pap ASCUS with positive HPV. This abnormal result triggers a colposcopy referral. The nearest gynecologist with colposcopy capability is at Phoebe Putney in Albany, 30 miles away. Colposcopy shows acetowhite changes; biopsy shows CIN 1. ASCCP guidelines support observation rather than immediate treatment for CIN 1 at her age, and she is scheduled for repeat HPV co-testing in 12 months.

Billing: the screening services (G0101, Q0091, G0123, G0476) are $0.1 The colposcopy (CPT 57452) and biopsy (57454) carry the standard Part B deductible and 20% coinsurance.2

Scenario #3: High-Risk History, Annual Screening

A 64-year-old woman in Cobb County has a history of CIN 2 treated with LEEP at age 58. That history places her in the high-risk category, requiring annual screening rather than every-24-months average-risk screening. Her gynecologist at Wellstar Women's Health orders an annual Pap test and HPV co-testing (G0101, Q0091, G0123, G0476).

Results: Pap NILM, HPV negative. Continued annual surveillance is recommended given her prior CIN 2 history. All screening services are $0.1

Scenario #4: Age 68, Discontinuation After Adequate Screening

A 68-year-old woman in DeKalb County has had three consecutive negative Pap tests at ages 60, 63, and 66, with the most recent within the past 5 years. She has documented adequate prior negative screening under USPSTF criteria and is appropriately a candidate for discontinuation. At her AWV at Emory, her physician documents the adequate prior screening history and the USPSTF Grade A recommendation against continued screening for women older than 65 with adequate prior negatives.

After shared decision-making, she elects to discontinue routine screening, and the physician documents the decision in the AWV personalized prevention plan. She understands that diagnostic evaluation remains available if symptoms develop, such as postmenopausal bleeding or abnormal discharge.

Common Problems and How to Avoid Them

Continuing Screening After 65 Without Reassessing

Many women 65 and older continue routine screening despite adequate prior negatives that would support discontinuation. AWV-based reassessment supports appropriate decisions.

Inadequate Documentation of Prior Screening

Discontinuation depends on adequate prior negative screening, but prior records are sometimes incomplete or unavailable. Without adequate documentation, continued screening is appropriate.

Post-Hysterectomy Screening Confusion

The hysterectomy exception above turns on whether the cervix was removed and why, and the record does not always document either clearly. Verifying the details supports appropriate decisions.

HPV Co-Testing Frequency Misunderstanding

HPV co-testing is covered every 5 years for women age 30 to 65, but some practitioners default to more frequent intervals. Annual HPV co-testing for low-risk women is generally not indicated.1

High-Risk Misclassification

Misclassification in either direction produces an incorrect screening frequency.

Cost-Sharing Surprise on Colposcopy Referral

Beneficiaries called back for colposcopy after abnormal screening sometimes do not expect the Part B deductible plus 20% coinsurance. Pre-referral counseling addresses expectations.2

Medicare Advantage Network Limits

Medicare Advantage plans may have gynecology and colposcopy network constraints. Out-of-network use can produce higher cost-sharing than Original Medicare.

Where to Get Help in Georgia

Learn More

Find personalized help understanding your Medicare cervical cancer screening coverage at brevy.com.

The information on Brevy.com is for educational purposes only and is not a substitute for professional legal, financial, or medical advice. Rules vary by state and program and change frequently. Always verify with the relevant agency or a qualified professional. Brevy is not a law firm, financial advisor, or healthcare provider.